Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P51
Within normal range
vs 2Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.76% |
| Q3 2025 | 25.78% |
| Q2 2025 | 264.46% |
| Q1 2025 | -204.23% |
| Q4 2024 | 33.29% |
| Q3 2024 | 33.49% |
| Q2 2024 | 48.20% |
| Q1 2024 | -741.94% |
| Q4 2023 | 67.80% |
| Q3 2023 | -297.49% |
| Q2 2023 | 120.69% |
| Q1 2023 | 67.93% |
| Q4 2022 | -261.75% |
| Q3 2022 | 210.26% |
| Q2 2022 | -41.81% |
| Q1 2022 | 65.58% |
| Q4 2021 | -11.62% |
| Q3 2021 | 10.88% |
| Q2 2021 | 10.75% |
| Q1 2021 | -129.83% |
| Q4 2020 | -13.02% |
| Q3 2020 | -173.18% |
| Q2 2020 | 141.55% |
| Q1 2020 | 2.76% |
| Q4 2019 | -938.43% |
| Q3 2019 | 128.64% |
| Q2 2019 | 72.18% |
| Q1 2019 | -87.15% |
| Q4 2018 | -491.44% |
| Q3 2018 | -238.52% |
| Q2 2018 | 144.25% |
| Q1 2018 | -24.13% |
| Q4 2017 | 70.01% |
| Q3 2017 | -324.17% |
| Q2 2017 | 355.71% |
| Q1 2017 | -109.96% |
| Q4 2016 | 438.74% |
| Q3 2016 | -4.78% |
| Q2 2016 | -254.61% |
| Q1 2016 | 176.09% |